Reviews/GLP-1 Receptor Agonists/Sustained heart rate increase of 2-4 beats per minute
Safety · GLP1-SAF-08 · v2
The studies here agree that GLP-1 receptor agonists raise resting heart rate and that the rise lasts, not just a brief blip. Where they disagree with the claim is the size of the rise. In the controlled human trials, liraglutide pushed heart rate up by about 6 to 8 beats per minute [5][8], and a heart-failure group rose by about 7 beats [11]. Only one 12-week study using wearables landed inside the claimed 2 to 4 beat range, at 3.2 beats [12]. So the panel accepted the phenomenon but found the specific 2 to 4 beat figure too low for the most-studied drugs, and that is why it did not carry the claim as written.
The corpus consistently shows a sustained resting-heart-rate increase with GLP-1 receptor agonists in the eligible human studies [5][8][11][12]. The magnitudes, however, mostly sit above the claimed band: liraglutide raised mean heart rate by 8.1 beats/min [5] and by 6.6 beats/min over 12 weeks [8], acute exenatide by 7.5 beats/min [8], and a HFrEF device cohort by 7 beats/min [11]. Only the 12-week wearable study reports a value inside the band at 3.2 beats/min [12]. Animal and ex-vivo work supports the direction and a direct sino-atrial mechanism [1][4][13] but supplies no human magnitude. The contested point: The division is entirely quantitative: the direction and persistence of the heart-rate rise are agreed, but most eligible primary data exceed the stated 2-4 bpm ceiling [5][8][11], with a single in-band estimate [12]. Whether the claim is best read as understating a real class effect or as refuted on its specific number is the point of tension.
All 17 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The specific magnitude '2-4 bpm' is contradicted by most included primary human data: liraglutide shows +8.1 bpm [5] and +6.6 bpm [8], and the HFrEF cohort +7 bpm [11]. Only one study [12] lands in-band, so the corpus arguably refutes the number rather than confirming it.
The claim is class-wide but the eligible human evidence is agent-skewed toward liraglutide; the only in-band value [12] comes from a wearable/causal-inference design, not a controlled trial, so the 2-4 bpm figure rests on the weakest design in the set.
Where it remains uncertain. Only the wearable study [12] at 3.2 beats/min falls inside the claimed band, so the corpus supports the effect while contradicting the stated magnitude.
Aleatory
Short-acting agents rise less than long-acting ones, so a single class number masks real drug-to-drug spread even within the included data.
Epistemic
Eligible primary human data are dominated by liraglutide [5][8]; semaglutide, dulaglutide and tirzepatide have no eligible human magnitude in the corpus.
Inferential
The only in-band estimate [12] is a wearable causal-inference study, not a controlled trial, so the 2-4 bpm reading rests on the least controlled design.
The load-bearing papers from a corpus of 17, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Demonstrates a sustained day-and-night resting-HR increase with liraglutide, but at 8.1 bpm, above the claimed 2-4 bpm.
“increased the mean HR (8.1 beats/min; P = 0.003), daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026)”
Panel auditInternal validity: medium · scope of inference: Overweight patients with stable CAD and newly diagnosed T2D on liraglutide.Key limitations: small n · magnitude exceeds 2-4 bpm · single agent liraglutide · CAD population
Shows a sustained 12-week resting-HR rise with liraglutide of 6.6 bpm, exceeding the claimed band.
“Twelve-week treatment with liraglutide increased RHR (+6.6 ± 2.1 BPM)”
Panel auditInternal validity: medium · scope of inference: T2DM patients on metformin and/or sulfonylureas; resting HR mechanisms.Key limitations: small n · magnitude exceeds 2-4 bpm · only exenatide and liraglutide
One-year sustained HR increase of 7 bpm in HFrEF, with a lower CI bound (4) only touching the top of the claimed range.
“GLP1RA use (vs no use) significantly increased heart rate by +7 beats/min (95% CI: 4-10 beats/min; P < 0.01)”
Panel auditInternal validity: medium · scope of inference: Patients with HFrEF and implanted cardiac devices, mostly diabetic.Key limitations: retrospective · HFrEF-specific population · magnitude exceeds 2-4 bpm · small n
3 of 17 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The direction and sustainment are well evidenced, but the specific 2-4 bpm magnitude is understated relative to most included primary data, so the claim as worded is not carried by the corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Class-wide magnitude across agents. The claim is class-wide but eligible primary data are liraglutide-heavy [5][8]; drug-level differences (short- vs long-acting) are only described in an excluded review [2]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A head-to-head controlled trial measuring resting heart rate across short- and long-acting GLP-1 receptor agonists in a common population.
Open question: What is the mean sustained resting-heart-rate increase for each GLP-1 receptor agonist measured under a common controlled protocol? Why it is still open: Eligible primary data are dominated by liraglutide at 6-8 bpm [5][8]; per-agent magnitudes for other drugs are absent in eligible form.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19